Clinical blockade of the Programmed Death-1 (PD-1, CD279) pathway using monoclonal antibodies (mAbs) was added to the first-line treatment arsenal for advanced non-small cell lung cancer (NSCLC) patients in 2016 (1). Here, PDCD1 is linked to non-small cell lung carcinoma.